A History of Bold Action
Forging our future on the foundation of a BOLD past
Amarin is built on a history of bold actions. Read below for highlights of our history as a company committed to being BOLD.
2008
Amarin Opens Research and Development Center
Amarin makes its entry into cardiovascular research and development and opens its R&D headquarters in Mystic, Connecticut.
2009
Amarin Receives SPA For Phase 3 MARINE Study
Receives Special Protocol Assessment for its Phase 3 MARINE study evaluating AMR-101’s ability to lower triglycerides.
2011
Amarin Commences 1st Patient In REDUCE-IT™ Trial
Commences first patient in REDUCE-IT, The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial.”
2012
Amarin Receives FDA Approval For VASCEPA® (Icosapent Ethyl)
Receives first FDA approval of VASCEPA® for its initial indication.
2013
Amarin launches commercially in the U.S.
2015
Amarin Announces Partnership With Eddingpharm
Amarin and Eddingpharm announce an agreement to develop and commercialize in China.
2016
Amarin Wins Right To Promote Under First Amendment In The U.S.
Amarin BOLDLY affirms its right to promote under the First Amendment Litigation Settlement Terms and enrolls the final patients into the REDUCE-IT™ study.
2017
Amarin Announces Partnership In Canada
Amarin and HLS Therapeutics announce an agreement to commercialize in Canada.
2018
Amarin Announces Results From REDUCE-IT™
Reports positive results from the study and files for FDA approval.
2019
VASCEPA® Approved For Expanded Indiction
Amarin receives FDA approval for its second indication.
2020
VASCEPA® Expansion Launches in the U.S.
2021
VAZKEPA® Approved By EMA And MHRA
Enters into the European market with approval from the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency.
2022
Amarin secures pricing and reimbursement for VAZKEPA® in the UK, Sweden, and Finland. TGA approval of VAZKEPA® is received in Australia
2023
VAZKEPA® is approved in New Zealand, Israel, and China.
Amarin announces an exclusive long-term agreement with Lotus Pharmaceuticals to distribute and commercialize VAZKEPA® across ten countries in Southeast Asia and South Korea. An exclusive marketing and commercial agreement is announced with Neopharm for VAZKEPA® in Israel, and reimbursement is secured in Spain, Scotland, and the Netherlands.
2023
2024
2024
Amarin's IP protection for VAZKEPA® in Europe extends into 2039.
Reimbursement is secured in Portugal, Italy, and Greece, with a partnership with Vianex. EddingPharm receives regulatory approval for VASCEPA® in Mainland China for the CVRR indication.
our vision
Rethinking Cardiovascular Care. Reducing Cardiovascular Risk.
Get to know Amarin
Who is Amarin? Amarin is a global pharmaceutical company that has developed and is pursuing additional treatments to help address cardiovascular disease. Amarin is relentless in its pursuit of scientific breakthroughs that can lead to revolutionary solutions that create a healthier world. Find out more about who we are, what we stand for and how we are making a difference in the lives of patients.
Where we are
Amarin is making a positive impact on cardiovascular health across the world. Find out where we're located.
Contact Us
Amarin seeks to collaborate with others to address cardiovascular risk and create value.
Company Profile
An international leader in the fight to address cardiovascular disease
Investor Relations
A BOLD investment in cardiometabolic health
Keeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.
Science and Health
Passionate about cardiometabolic science and health
Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.
Working at Amarin
A BOLD place for entrepreneurial careers
Are you interested in joining Amarin and being part of our BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide? Click here for more information about our culture, career opportunities, benefits and more.
ALL-NP-00015 1/23
©2025 Amarin Pharmaceuticals Ireland Limited. All rights reserved.
AMARIN, VASCEPA, VAZKEPA and REDUCE-IT names and logos are trademarks of Amarin Pharmaceuticals Ireland Limited. | ALL-NP-00014 1/23
Get In Touch
Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:
Follow Us
Follow Amarin on our social channels for the latest company news, product campaigns and industry updates:
